DOCS Stock Recent News

In the latest trading session, Doximity (DOCS) closed at $59.7, marking a -2.13% move from the previous day.

Doximity shares have dropped nearly 25% from February highs, despite strong Q4 earnings and 17% revenue growth year-over-year. Analyst sentiment is mixed, and insider selling has notably increased in 2025. Doximity boasts a robust balance sheet with $915 million in cash, no long-term debt, and an impressive rise in free cash flow in its last reported quarter.

Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

In the closing of the recent trading day, Doximity (DOCS) stood at $59.38, denoting a -1.44% move from the preceding trading day.

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2025 after market close on August 7, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before.

Doximity (DOCS) concluded the recent trading session at $61.55, signifying a +2.24% move from its prior day's close.

Dr Martens PLC (LSE:DOCS) said trading since the start of the financial year has been in line with expectations, with guidance for its current financial year unchanged and profit expected to be weighted to the second half The FTSE 250-listed footwear manufacturer and retailer reported a "positive" performance for its direct-to-consumer business in the Americas, particularly in its shops and full-price sales, though the UK continued to see "a challenging trading backdrop". In Europe, the Middle East and Africa, trading was mixed, while the Asia Pacific region delivered strong growth, led by South Korea.

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. (NYSE: DOCS) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.

I have a price target of $85 for Doximity by summer 2026. There is lots to be bullish about. Doximity's fundamentals are strong: zero debt, a large cash cushion, and robust free cash flow generation support my bullish outlook. Despite unimpressive 11% revenue growth guidance, DOCS surpasses the Rule of 40 with a Rule of 58, justifying a premium valuation.

Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close.